Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hepatology
Volume 2017, Article ID 5834182, 8 pages
https://doi.org/10.1155/2017/5834182
Clinical Study

HCV Integrated Care: A Randomized Trial to Increase Treatment Initiation and SVR with Direct Acting Antivirals

1VA San Diego Healthcare System, San Diego, CA, USA
2University of California, San Diego, San Diego, CA, USA

Correspondence should be addressed to Erik J. Groessl; ude.dscu@lsseorge

Received 15 April 2017; Revised 10 June 2017; Accepted 12 June 2017; Published 27 July 2017

Academic Editor: Maria Buti

Copyright © 2017 Erik J. Groessl et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. M. Denniston, R. B. Jiles, J. Drobeniuc et al., “Chronic hepatitis C virus infection in the United States, national health and nutrition examination survey 2003 to 2010,” Annals of Internal Medicine, vol. 160, no. 5, pp. 293–300, 2014. View at Publisher · View at Google Scholar
  2. S. D. Holmberg, P. R. Spradling, A. C. Moorman, and M. M. Denniston, “Hepatitis C in the United States,” The New England Journal of Medicine, vol. 368, no. 20, pp. 1859–1861, 2013. View at Publisher · View at Google Scholar
  3. Polaris Observatory HCVC, “Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study,” Lancet Gastroenterol Hepatol, vol. 2, pp. 161–176, 2017. View at Google Scholar
  4. G. L. Davis, M. J. Alter, H. El-Serag, T. Poynard, and L. W. Jennings, “Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression,” Gastroenterology, vol. 138, no. 2, pp. 513–e6, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Colombo, “Interferon-free therapy for hepatitis C: the hurdles amid a golden era,” Digestive and Liver Disease, vol. 47, no. 9, pp. 727–733, 2015. View at Publisher · View at Google Scholar
  6. B. D. Smith, R. L. Morgan, G. A. Beckett et al., “Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965,” MMWR Recommendations and Reports, vol. 61, pp. 1–32, 2012. View at Google Scholar · View at Scopus
  7. B. D. Smith, R. L. Morgan, G. A. Beckett, Y. Falck-Ytter, D. Holtzman, and J. W. Ward, “Hepatitis C virus testing of persons born during 1945–1965: recommendations from the centers for disease control and prevention,” Annals of Internal Medicine, vol. 157, no. 11, pp. 817–822, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. J. A. Gutierrez, E. J. Lawitz, and F. Poordad, “Interferon-free, direct-acting antiviral therapy for chronic hepatitis C,” Journal of Viral Hepatitis, vol. 22, no. 11, pp. 861–870, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. G. N. Ioannou, L. A. Beste, and P. K. Green, “Similar effectiveness of boceprevir and telaprevir treatment regimens for hepatitis C virus infection on the basis of a nationwide study of veterans,” Clinical Gastroenterology and Hepatology, vol. 12, no. 8, pp. 1371–1380, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. L. Henry and Z. Younossi, “Patient-reported and economic outcomes related to sofosbuvir and ledipasvir treatment for chronic hepatitis C,” Expert Review of Pharmacoeconomics and Outcomes Research, vol. 16, no. 6, pp. 659–665, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Judd, A. M. Liubakka, A. Pavle, S. Patel, Z. Hakim, and F. Antaki, “Assessing key barriers to treatment of chronic hepatitis C virus (HCV) with next generation agents in a veteran population,” Gastroenterology, vol. 146, no. S-737, 2014. View at Publisher · View at Google Scholar
  12. J. Dever, J. Ducom, A. Ma et al., “Engagement in care of high risk hepatitis C patients with interferon-free therapies,” Hepatology, vol. 62, no. 483A, 2015. View at Google Scholar
  13. S. Barua, R. Greenwald, J. Grebely, G. J. Dore, T. Swan, and L. E. Taylor, “Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States,” Annals of Internal Medicine, vol. 163, no. 3, pp. 215–223, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. W. Venteicher, “Medicaid patients denied new hepatitis C cures,” 2014, Chicago Tribune.
  15. J. P. Meyer, Y. Moghimi, R. Marcus, J. K. Lim, A. H. Litwin, and F. L. Altice, “Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum,” International Journal of Drug Policy, vol. 26, no. 10, pp. 922–935, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. M. M. Ford, N. Johnson, P. Desai, E. Rude, and F. Laraque, “From care to cure: demonstrating a model of clinical patient navigation for hepatitis C care and treatment in high-need patients,” Clinical Infectious Diseases, vol. 64, no. 5, pp. 685–691, 2017. View at Publisher · View at Google Scholar
  17. J. M. Levin, S. Dabirshahsahebi, and M. Bauer, “Retrospective analysis of hepatitis C infected patients treated through an integrated care model,” World Journal of Gastroenterology, vol. 22, no. 38, pp. 8558–8567, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. E. J. Groessl, S. B. Ho, S. M. Asch, C. J. Stepnowsky, D. Laurent, and A. L. Gifford, “The hepatitis C self-management program: sustainability of primary outcomes at 1 year,” Health Education and Behavior, vol. 40, no. 6, pp. 730–740, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. E. J. Groessl, M. Sklar, D. D. Laurent, K. Lorig, T. G. Ganiats, and S. B. Ho, “Cost-effectiveness of the hepatitis C self-management program,” Health Education & Behavior, vol. 44, no. 1, pp. 113–122, 2017. View at Publisher · View at Google Scholar
  20. E. J. Groessl, K. R. Weingart, A. L. Gifford, S. M. Asch, and S. B. Ho, “Development of the hepatitis C self-management program,” Patient Education and Counseling, vol. 83, no. 2, pp. 252–255, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. E. J. Groessl, K. R. Weingart, C. J. Stepnowsky, A. L. Gifford, S. M. Asch, and S. B. Ho, “The hepatitis C self-management programme: a randomized controlled trial,” Journal of Viral Hepatitis, vol. 18, no. 5, pp. 358–368, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. E. J. Groessl, M. Sklar, R. C. Cheung, N. Bräu, and S. B. Ho, “Increasing antiviral treatment through integrated hepatitis C care: a randomized multicenter trial,” Contemporary Clinical Trials, vol. 35, no. 2, pp. 97–107, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. S. B. Ho, “Hepatitis C: clinical management,” Federal Practitioner, pp. 17–21, 2003. View at Google Scholar
  24. S. B. Ho, N. Bräu, R. Cheung et al., “Integrated care increases treatment and improves outcomes of patients with chronic hepatitis C virus infection and psychiatric illness or substance abuse,” Clinical Gastroenterology and Hepatology, vol. 13, no. 11, pp. 2005–2014, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. S. B. Ho, E. Groessl, A. Dollarhide, S. Robinson, D. Kravetz, and E. Dieperink, “Management of chronic hepatitis c in veterans: the potential of integrated care models,” American Journal of Gastroenterology, vol. 103, no. 7, pp. 1810–1823, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. F. Kanwal, T. Hoang, B. M. R. Spiegel et al., “Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatent factors,” Hepatology, vol. 46, no. 6, pp. 1741–1749, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. H. S. Yee, S. L. Currie, J. M. Darling, and T. L. Wright, “Management and treatment of hepatitis C viral infection: recommendations from the department of veterans affairs hepatitis C resource center program and the national hepatitis C program office,” American Journal of Gastroenterology, vol. 101, no. 10, pp. 2360–2378, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. E. Lawitz and E. J. Gane, “Sofosbuvir for previously untreated chronic hepatitis C infection,” New England Journal of Medicine, vol. 369, no. 7, pp. 678-679, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Martinot-Peignoux, C. Stern, S. Maylin et al., “Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis c virus receiving pegylated interferon and ribavirin,” Hepatology, vol. 51, no. 4, pp. 1122–1126, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. L. A. Beste and G. N. Ioannou, “Prevalence and treatment of chronic hepatitis C virus infection in the us department of veterans affairs,” Epidemiologic Reviews, vol. 37, no. 1, pp. 131–143, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. E. Woltmann, A. Grogan-Kaylor, B. Perron, H. Georges, A. M. Kilbourne, and M. S. Bauer, “Comparative effectiveness of collaborative chronic care models for mental health conditions across primary, specialty, and behavioral health care settings: systematic review and meta-analysis,” American Journal of Psychiatry, vol. 169, no. 8, pp. 790–804, 2012. View at Publisher · View at Google Scholar · View at Scopus